Centessa Pharmaceuticals announced updates on its OX2R agonist pipeline, including ORX750, ORX142, and ORX489, with significant clinical milestones anticipated in 2025. The company aims to ...

Dr. Kanes, who previously held the CMO position at Sage Therapeutics, is set to enhance Centessa's efforts in advancing its portfolio of orexin receptor 2 (OX2R) agonists, which are aimed at ...